ROCKVILLE, Md. — Novavax Inc. confirmed March 24 that its potential H1N1 flu vaccine prompted an immune response in patients during a midstage study.
In December, the company reported positive results from 500 patients in the study being conducted in Mexico. The full results from 1,000 volunteers in the study confirm those safety and immune response results.
Novavax has said its vaccine can be grown in weeks instead of the months it takes to make a traditional vaccine. Most flu vaccines are grown inside chicken eggs, but Novavax uses genetically engineered virus-like particles, which resemble a virus but do not have the genetic material a virus needs to reproduce itself.
The company is conducting a larger, 3,500-person study.